The Lymphoma SPORE Developmental Research Program supports innovative translational research projects that may develop into full projects. To achieve this objective, the Developmental Research Program will solicit submission of novel projects with translational potential in lymphoma and CLL. Candidate projects will be reviewed by a panel with expertise in translational research, and the most promising proposals will be selected for support with the intent that they will either develop into full SPORE projects or secure peerreviewed funding as independent projects. The leaders of developmental projects will be fully incorporated into the SPORE and be able to take advantage of the expertise of SPORE investigators in bench to bedside translation. In the last 4 years the DRP has supported a broad portfolio of projects from 8 different departments at BCM and 3 at TMH, as well as from other institutions in the Texas Medical Center (one award to Rice University and one in collaboration with MD Anderson). DRP projects have produced 25 publications and have been leveraged to obtain 10 new peer-reviewed grants.The program directors, in collaboration with the Administrative Core will continue to use this program to test and develop novel strategies. We will continue to collect data to evaluate the success of the DRP program, allowing evaluation by the lAB and EAB. Two projects in this SPORE renewal have an aim that developed from a Developmental Research Program project, indicating past success.

Public Health Relevance

Tfie program supports innovative and scientifically meritorious pilot projects to explore novel ideas in lymphoma and CLL research. These pilot studies may develop into full projects if they demonstrate potential to be translated into clinicallyi important applications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Rouce, Rayne H; Heslop, Helen E (2016) Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov 6:579-80
Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34
Bollard, Catherine M; Heslop, Helen E (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:3331-40
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2016) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol :
Ramos, Carlos A; Heslop, Helen E; Brenner, Malcolm K (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165-83
Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 126:2588-96
Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81
Zhou, Xiaoou; Naik, Swati; Dakhova, Olga et al. (2016) Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther 24:823-31
Eckstein, Olive S; Wang, Linghua; Punia, Jyotinder N et al. (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44:740-4
Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1

Showing the most recent 10 out of 218 publications